Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
MTA 协同 PRMT5 抑制剂 BMS-986504 与 KRAS 抑制剂联合使用是治疗 MTAP 缺失 KRAS 突变型胰腺癌的有效策略
期刊:Cancer Research
影响因子:16.6
doi:10.1158/0008-5472.CAN-25-1507
Drizyte-Miller, Kristina; Engstrom, Lars D; Klomp, Jeffrey A; Stalnecker, Clint A; Stamey, Addison G; Taylor, Khalilah E; Roach, Mallory K; Robb, Ryan; Waters, Laura M; Calinisan, Andrew; Degan, Seamus; Chang, Wen-Hsuan; Helu, Xousaen M; Nguyen, David; Baldelli, Elisa; Pierobon, Mariaelena; Petricoin, Emanuel F; Briere, David M; Hallin, Jill; Christensen, James G; Bryant, Kirsten L; Cox, Adrienne D; Olson, Peter; Der, Channing J
